Moderna's mRNA-1010 flu vaccine has shown
superior efficacy in late-stage trials compared to the standard shot, beating both rival GSK and an approved competitor. This paves the way for a
combination Covid shot, and it proves the effectiveness of investment in mRNA vaccines against pandemic influenza viruses. Moderna has also been
awarded $590M by the U.S. Health and Human Services (HHS) to accelerate the development of mRNA-based bird flu vaccines, despite the
cancellation of previous funding. Amidst rising anti-vaccine sentiments, insiders fear the potential negative impact such could have on Moderna. Questions have been raised on the safety of mRNA vaccines, particularly regarding potential myocarditis risk in young men. Moderna's will undergo another evaluation by the FDA on this issue. On the financial front, there has been a reduction of stock holdings in Moderna by Quattro Financial Advisors LLC. While fluctuations in Moderna's shares have been noted,
positive results from the mRNA flu vaccine trials have seen a recent boost to the company's health in the market.
Moderna MRNA News Analytics from Thu, 05 Sep 2024 07:00:00 GMT to Sat, 05 Jul 2025 13:14:01 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor 3
